Stomach Cancer News and Research RSS Feed - Stomach Cancer News and Research

Stomach cancer or gastric cancer affects around 7,000 people each year in the UK. Stomach cancer is difficult to detect in the early stages because the initial symptoms are also seen in less serious conditions such as persistent indigestion, heart burn, trapped wind, burping and stomach ache.
Poorly-designed animal study threatens validity of preclinical research

Poorly-designed animal study threatens validity of preclinical research

Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to new a study from McGill University in Canada. [More]
New online Smart Map shows progress in UK lung cancer care

New online Smart Map shows progress in UK lung cancer care

Roy Castle Lung Cancer Foundation (RCLCF) today launches a new online Smart Map that shows how standards of lung cancer care vary throughout the UK.(1) The resource, available at http://www.roycastle.org/how-we-help/our-campaigns/improving-treatment-and-care/interactive-map, is based on the latest research by the National Lung Cancer Audit (NLCA), published in December 2014.2 This shows encouraging improvements have been made in standards of lung cancer care across multiple UK regions. [More]
EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood. [More]
Tadpole Endoscope improves diagnostic procedures for various cancers

Tadpole Endoscope improves diagnostic procedures for various cancers

Engineers have developed a new medical device aimed at improving diagnostic procedures for various cancers: the Tadpole Endoscope (TE). [More]
MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer. [More]
Study reveals that miR-7 suppresses gastric cancer by inhibiting key signaling pathway

Study reveals that miR-7 suppresses gastric cancer by inhibiting key signaling pathway

A study in The Journal of Cell Biology reveals that the microRNA miR-7 suppresses gastric (stomach) cancer by inhibiting a key signaling pathway, and that this protective mechanism is compromised by the cancer-causing bacterium H. pylori. Finding drugs capable of inducing miR-7 could therefore prove to be an effective treatment against the progression of gastric cancer. [More]
Eradicating H. pylori bacterium with short course of therapy may help prevent gastric cancer

Eradicating H. pylori bacterium with short course of therapy may help prevent gastric cancer

A new review published in the Cochrane Library, indicates that eradicating Helicobacter pylori bacterium-- the main cause of stomach ulcers - with a short course of therapy comprising two commonly used medicines may help to reduce the risk of gastric cancer. Stomach, or gastric, cancer is the third most common cause of death from cancer worldwide, and people who are infected with the Helicobacter pylori bacterium are more likely to develop the disease. [More]
Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America. [More]

New breath test could help diagnose oesophageal and gastric cancer in minutes

Researchers have devised a breath test that can help doctors diagnose the early signs of oesophageal and gastric cancer in minutes. [More]
Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Around half of the global population is chronically infected with the stomach bacterium Helicobacter pylori, almost 1 percent of whom go on to develop gastric adenocarcinoma, one of the deadliest forms of cancer. Usually it takes many decades for the cancer to develop, making it difficult to pinpoint exactly how it is linked to an infection. [More]
Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Game changing, breakthrough early cancer detection technology presented at ASCO 2015

Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu and the Anpac research team are introducing what the 2015 Nobel Prize Laureate Summit on Biomedical Science (NPLS) organizers published as, "game changing" and "breakthrough" early cancer detection technology research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29 – June 2, 2015. [More]
Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells. [More]
Study: New cases of cancer rising globally, but death rates falling in many countries

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries. [More]
New study shows ulcer-causing bacteria can directly interact with stomach stem cells

New study shows ulcer-causing bacteria can directly interact with stomach stem cells

The ulcer-causing bacterium Helicobacter pylori can directly interact with stomach stem cells, causing the cells to divide more rapidly, according to a new study by researchers at the Stanford University School of Medicine. [More]
Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014. [More]

Lightpoint Medical raises $3.1M in Series A financing round for medical imaging technology

Lightpoint Medical, a developer of innovative surgical imaging technologies, announced today that the company has raised £2 million ($3.1 million) in a Series A financing round. [More]
Study finds striking gap in cancer survival between countries and regions

Study finds striking gap in cancer survival between countries and regions

The CONCORD-2 study, published in The Lancet, reports 5-year survival estimates for 25·7 million cancer patients diagnosed with one of 10 common cancers and 75 000 children diagnosed with acute lymphoblastic leukaemia between 1995 and 2009, using individual patient data from 279 cancer registries in 67 countries. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday). [More]
Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical Services Holdings Limited, an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the Company has received relevant government approvals to establish a free-standing radiotherapy cancer center, Datong Meizhong Jiahe Cancer Center ("Datong Center") in Datong City, Shanxi Province. [More]
Advertisement
Advertisement